NCT06219408 CIH Stepped Care for Co-occurring Chronic Pain and PTSD
| NCT ID | NCT06219408 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Chronic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-02-18 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the feasibility, acceptability, appropriateness, and retention of patient participants of a CIH Stepped Care approach for co-occurring chronic pain and PTSD vs. treatment as usual in two primary care settings (one rural and one urban). Researchers will compare CIH Stepped Care to treatment as usual. Participants will complete assessments at baseline, 3-months, 6-months, and 9-months, and those in the CIH Stepped Care condition will participate in the intervention while also completed assessments every 2-weeks, which helps determine their treatment. We hypothesize that, at 6-months, CIH Stepped Care will be feasible, acceptable, and appropriate (defined by an average of 4/5 on each measure) to patients and clinic employees and result in at least 70% of individuals be retained in each condition (n=21 per condition).
Eligibility Criteria
Inclusion Criteria In order to be eligible to participate in this study, clinic employees must meet all of the following criteria: 1. Aged 18 years or older 2. A clinic employee and/or trainee In order to be eligible to participate in this study, patients must meet all of the following criteria: 1. Aged 18 years or older 2. English-speaking 3. A patient at the clinic from which recruitment occurs 4. Endorse chronic pain (defined as experiencing pain on more than half of the days of the past 3-months) 5. Endorse at least moderate pain severity and interference (defined as at least an average of 4 on the PEG) 6. Endorse at least 31 on the PCL-5, in combination with a Criterion A traumatic event. If we have difficulties in recruiting individuals who meet our PTSD diagnosis criteria, we will modify this criteria by removing the requirement of a Criterion A traumatic event, and require a destabilizing life event instead. 4.2 Exclusion Criteria There are no exclusion criteria for clinic employees. Patients who meet any of the following criteria will be excluded from participation in this study: 1. In current treatment for chronic pain and/or PTSD at their respective clinic 2. Past 2-week suicidal intention at screening 3. Severe cognitive impairment preventing individual from participating
Contact & Investigator
David Reed, PhD
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT06219408 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06219408 currently recruiting?
Yes, NCT06219408 is actively recruiting participants. Contact the research team at davider2@uw.edu for enrollment information.
Where is the NCT06219408 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06219408 clinical trial?
NCT06219408 is sponsored by University of Washington. The principal investigator is David Reed, PhD at University of Washington. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.